cSCC Gene Expression Assay for Recurrence and Metastasis Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the risk of recurrence and metastasis in cutaneous squamous cell carcinoma (cSCC) are inadequate, failing to accurately identify high-risk patients who may benefit from adjuvant therapies and leading to overtreatment of low-risk cases.
Innovation Solution
A gene expression profile (GEP) assay is developed to classify cSCC tumors into low (Class 1), moderate (Class 2A), or high (Class 2B) risk of metastasis by measuring the expression levels of 20-40 genes, including ALOX12, BBC3, BHLHB9, GTPBP2, and others, combined with clinical risk factors to guide adjuvant radiotherapy decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical and pathologic features are used to identify high-risk cSCC patients, then adjuvant treatment can be offered to those at risk, but 30-40% of recurrences are missed and many high-risk features do not lead to recurrence
Solution Approach 1:
The patent transitions from using clinical and pathologic parameters to measuring gene expression levels as the predictive parameter. Specifically, it quantifies the expression levels of 40 genes (including ALOX12, BBC3, BHLHB9, GTPBP2, and others) to create a molecular signature that accurately predicts recurrence and metastasis risk, thereby improving both reliability and measurement precision of risk stratification.
2Reliability
If adjuvant therapy is offered to all high-risk patients, then metastasis risk is reduced, but low-risk patients with high-risk features undergo unnecessary treatment
Solution Approach 1:
The patent changes the predictive parameter from complex clinical-pathologic feature assessment to a standardized gene expression profile measurement. The 40-gene signature provides a quantitative, objective metric that simplifies treatment decision-making while improving prediction accuracy, allowing clinicians to identify true high-risk patients without overtreatment of low-risk cases.
3Measurement precision
If gene expression analysis of 40 genes is performed, then risk stratification accuracy is improved, but assay complexity and cost increase
Solution Approach 1:
The patent segments the 40-gene expression profile into distinct risk categories (Class 1: low risk, Class 2A: moderate risk, Class 2B: high risk), each with specific metastasis-free survival probabilities. This segmentation transforms complex gene expression data into actionable clinical risk stratification, improving measurement precision while providing a structured framework that manages assay complexity through standardized classification.
Data Source
AI summary
The present disclosure relates to methods for predicting the risk of recurrence and/or metastasis, or both in primary cutaneous squamous cell carcinoma (cSCC).